.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EE02_Cobimetinib.Cobimetinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EE02_Cobimetinib.Cobimetinib| name: | Cobimetinib |
| ATC code: | L01EE02 | route: | oral |
| n-compartments | 2 |
Cobimetinib is an oral, selective inhibitor of MEK1 and MEK2, which are components of the MAPK/ERK pathway. It is primarily used in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600 mutation. Cobimetinib is approved by the FDA and EMA for this indication.
Pharmacokinetic parameters reported in adult patients with advanced solid tumors, primarily metastatic melanoma. Data represent population PK results following multiple oral doses.
Lieu, CH, et al., & Tabernero, J (2017). A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. The oncologist 22(9) 1024–e89. DOI:10.1634/theoncologist.2017-0175 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28592615